
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ODC CRISPR/Cas9 KO Plasmid (h) | sc-401055 | 20 µg | $397.00 |
ODC1 encodes ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis that converts ornithine to putrescine, supporting production of spermidine and spermine required for DNA replication, chromatin organization, and translation. ODC activity is tightly controlled by antizyme-mediated degradation and integrates with amino acid metabolism, mTOR-linked growth signaling, and cell-cycle progression. Dysregulated polyamine metabolism and elevated ODC1 expression are frequently associated with proliferative phenotypes, metabolic adaptation, and oncogenic transcriptional programs, making ODC1 a useful node for studying growth control and stress responses. ODC1 perturbation also informs research on apoptosis, oxidative stress buffering, and immune or inflammatory signaling where polyamines modulate gene expression and cellular fitness.
ODC CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ODC1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ODC1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ODC1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ODC protein expression.
This CRISPR knockout system enables efficient generation of ODC1-deficient cell models for investigation of ODC signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.